Johnson & Johnson Reports Q3 Earnings Miss Amid Investor Investigation
What happened
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson securities. Separately, Johnson & Johnson reported its third-quarter 2026 financial results on October 13, 2026. The company reported that sales in its MedTech division increased 2.5% to $8.64 billion, falling short of analyst expectations. Net earnings declined 95.9% year-over-year to $210 million, primarily due to special charges related to proposed talc litigation and acquisition expenses.
From pr-inside.com
Why it matters
The financial results highlighted continued weakness in the medical devices business, including pricing pressures in China and budget constraints in Europe. Following the Q3 announcement, Johnson & Johnson's stock price declined approximately 5.7%. The ongoing securities investigation adds legal liabilities for the company.
From pr-inside.com
Who's involved
- Johnson & JohnsonU.S multinational manufacturer whose Q3 results were reported and who is subject to an investor investigation.
- New York CityLocation where the general news report referencing Johnson & Johnson was published.
- SECRegulatory body that enforces mandatory financial and disclosure regulations on Johnson & Johnson.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Johnson & JohnsonSpeculative
The earnings miss and securities investigation could trigger stock decline and increase legal liabilities.
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
New York City
most populous city in the United States
Related events
- Johnson & Johnson filed recent stock holdings with the SEC on October 15, 2026.
- Institutional investors boosted their stake in Johnson & Johnson (JNJ) shares, highlighting the company's drug profits and balance sheet in filings with the SEC.
- Johnson & Johnson and Bank of America Merrill Lynch participated in the Q3 earnings season on October 7, 2026.
- A fund trimmed its position in Johnson & Johnson (JNJ) stock and disclosed the transaction via financial filings with the SEC.